187 related articles for article (PubMed ID: 21034671)
1. Neurokinin-1 receptor: a new promising target in the treatment of cancer.
Muñoz M; Coveñas R
Discov Med; 2010 Oct; 10(53):305-13. PubMed ID: 21034671
[TBL] [Abstract][Full Text] [Related]
2. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
Muñoz M; Martinez-Armesto J; Coveñas R
Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
[TBL] [Abstract][Full Text] [Related]
3. Involvement of substance P and the NK-1 receptor in cancer progression.
Muñoz M; Coveñas R
Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301
[TBL] [Abstract][Full Text] [Related]
4. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
5. The NK-1 receptor: a new target in cancer therapy.
Muñoz M; Rosso M; Coveñas R
Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668
[TBL] [Abstract][Full Text] [Related]
6. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
7. The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile.
Muñoz M; Rosso M; González A; Saenz J; Coveñas R
Peptides; 2010 Sep; 31(9):1643-8. PubMed ID: 20542069
[TBL] [Abstract][Full Text] [Related]
8. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
Muñoz M; Coveñas R
World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
[TBL] [Abstract][Full Text] [Related]
9. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage.
Esteban F; Muñoz M; González-Moles MA; Rosso M
Cancer Metastasis Rev; 2006 Mar; 25(1):137-45. PubMed ID: 16680578
[TBL] [Abstract][Full Text] [Related]
10. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
[TBL] [Abstract][Full Text] [Related]
11. A new frontier in the treatment of cancer: NK-1 receptor antagonists.
Muñoz M; Rosso M; Coveñas R
Curr Med Chem; 2010; 17(6):504-16. PubMed ID: 20015033
[TBL] [Abstract][Full Text] [Related]
12. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Munoz M; Covenas R; Esteban F; Redondo M
J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
[TBL] [Abstract][Full Text] [Related]
13. NK-1 as a melanoma target.
Muñoz M; Bernabeu-Wittel J; Coveñas R
Expert Opin Ther Targets; 2011 Jul; 15(7):889-97. PubMed ID: 21592000
[TBL] [Abstract][Full Text] [Related]
14. Involvement of substance P and the NK-1 receptor in human pathology.
Muñoz M; Coveñas R
Amino Acids; 2014 Jul; 46(7):1727-50. PubMed ID: 24705689
[TBL] [Abstract][Full Text] [Related]
15. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
Munoz M; Recio S; Rosso M; Redondo M; Covenas R
J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
[TBL] [Abstract][Full Text] [Related]
16. A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma.
Brener S; González-Moles MA; Tostes D; Esteban F; Gil-Montoya JA; Ruiz-Avila I; Bravo M; Muñoz M
Anticancer Res; 2009 Jun; 29(6):2323-9. PubMed ID: 19528498
[TBL] [Abstract][Full Text] [Related]
17. Substance P regulates PTH secretion through the neurokinin-1 receptor.
Galvin RJ; Babbey LE; Hipskind PA; Lamar T; George CA; Baez M; Gitter BD
Biochem Biophys Res Commun; 2000 Apr; 270(1):230-4. PubMed ID: 10733932
[TBL] [Abstract][Full Text] [Related]
18. NK-1 receptor antagonists: a new generation of anticancer drugs.
Munoz M; Covenas R
Mini Rev Med Chem; 2012 Jun; 12(7):593-9. PubMed ID: 22512565
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Muñoz M; Coveñas R
Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
[TBL] [Abstract][Full Text] [Related]
20. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
